Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Healthy
Interventions: PF-06946860, Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Prolonged QTc Interval
Interventions: Estetrol 20 mg, Estetrol 100 mg, Placebo, Moxifloxacin 400 mg; Drug
Lead sponsor: Estetra; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Safety, Healthy Subjects
Interventions: MEDI9314, placebo; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Hashimoto Disease
Interventions: MYMD-1, Placebo; Drug
Lead sponsor: TNF Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Clearwater, Florida

Conditions: Anthrax
Interventions: Doxycycline and Valortim, Placebo Antibiotic and Valortim, Placebo Antibiotic and Placebo Valortim; Drug
Lead sponsor: PharmAthene, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteers (Part 1), Major Depressive Disorder (Part 2)
Interventions: HT-2157, Placebo; Drug
Lead sponsor: Dart NeuroScience, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Homeostasis, Bone and Bones
Interventions: Dexlansoprazole, Esomeprazole, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: Up to 75 Years · Female only
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 12
States / cities: San Diego, California • Walnut Creek, California • Lakewood, Colorado + 9 more

Conditions: Zika Virus Infection
Interventions: IXIARO, Placebo, YF Vax 17D Strain, Zika Virus Purified Inactivated Vaccine (ZPIV); Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Healthy Volunteers
Interventions: TAK-004, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: ECG Effects
Interventions: Buprenorphine transdermal patch, Naltrexone tablet, Placebos (for TDS and for naltrexone and for moxifloxacin), Moxifloxacin tablet; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 328 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Parkinson's Disease
Interventions: Rasagiline, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 20 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: 0.15 mg PF-06649751, 0.5 mg PF-06649751, 1.5 mg PF-06649751, 1.5 mg PF-06649751 21 Days, 3.0 mg PF-06649751, 5.0 mg PF-06649751, 8.0 mg PF-06649751, 1.5 mg PF-06649751 in healthy Japanese subjects; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Procedural Sedation
Interventions: Remimazolam, Placebo; Drug
Lead sponsor: Paion UK Ltd.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: BT-600, BT-600 Placebo; Combination Product
Lead sponsor: Biora Therapeutics, Inc.; Industry
Eligibility: 19 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Meningococcal Vaccine
Interventions: rLP2086, Havrix (HAV), Saline; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 3,596 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 62
States / cities: Birmingham, Alabama • Dothan, Alabama • Harrisburg, Arkansas + 42 more

Conditions: Malaria
Interventions: PfSPZ Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Baltimore, Maryland • Bethesda, Maryland

Conditions: Healthy Volunteers
Interventions: Fasinumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Volunteers, Pharmacokinetics of ASP015K
Interventions: ASP015K, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Macular Degeneration, Age-related Macular Degeneration
Interventions: Pazopanib eye drops and Allergen Refresh Plus eye drops; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 2
States / cities: Fargo, North Dakota • Austin, Texas

Conditions: Chronic Renal Insufficiency
Interventions: LHW090, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Tennessee

Conditions: Mydriasis, Dilation
Interventions: Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle; Drug
Lead sponsor: Opus Genetics, Inc; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Longwood, Florida • Athens, Ohio

Conditions: Nutritional Status
Interventions: GSK1325756; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Parkinson Disease, Healthy
Interventions: Raclopride; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects

Effect of Estetrol Monohydrate (E4) on QTc Interval

Safety and Tolerability of MEDI9314 as Single Ascending Dose in Healthy Subjects

Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects

Ph1 Study of Valortim and Doxycycline in Humans

Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder

Effect of Dexlansoprazole on Bone Homeostasis

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

A First-In-Human Study of TAK-004 in Healthy Adults

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline

A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

A Trial of Intranasal Remimazolam Pharmacokinetics, Pharmacodynamics, Safety and Bioavailability

Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects

BT-600 Single and Multiple Ascending Oral Doses in Healthy Adult Subjects

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults

Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy Subjects

A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.

An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump Inhibitors

The Role of Dopamine in Motor Learning in Healthy Subjects and Patients With Parkinson's Disease